Hims & Hers Health Inc. (NYSE:HIMS) shares edged lower in Tuesday’s premarket session.

The company recently broadened its GLP-1 offerings and disclosed a planned share sale by its chief financial officer.

A recent filing showed Chief Financial Officer Oluyemi Okupe plans to sell nearly $5 million in stock.

The filing comes after Hims & Hers expanded into Novo Nordisk (NYSE:NVO) GLP-1 treatments.

Expansion Into GLP-1 Treatments

Hims & Hers Health recently broadened access to several GLP-1 drugs from Novo Nordisk.

The lineup includes Wegovy injections in multiple strengths. The company also plans to add a 7.2 mg dose soon.

Patients can also access oral GLP-1 options across several dosage levels. Pricing starts at $149 per month.

Providers will determine eligibility based on clinical assessments. Some patients may achieve meaningful weight loss through these treatments.

Wegovy Pill And Broader Access

The platform now includes the newly launched Wegovy pill. It is currently the only FDA-approved oral GLP-1 option for weight management.

The move aims to meet rising demand for convenient obesity treatments. The company seeks to streamline access through its digital platform.

Hims & Hers Technical Analysis

At $20.27, the stock is trading 8.4% below its 20-day simple moving average (SMA) of $22.15, suggesting short-term weakness. It is also 28% below its 100-day SMA of $28.21, indicating a bearish intermediate trend.

The relative strength index (RSI) currently sits at 47.48, suggesting neutral momentum, while the moving average convergence divergence (MACD) shows a bearish signal, with the MACD at -0.3562 below the signal line of -0.1197. This indicates that selling pressure is currently dominating.

  • Key Resistance: $22.15 — This level has historically acted as a barrier for upward movement.
  • Key Support: $20.00 — A critical level where buying interest may emerge.

Over the past 12 months, Hims & Hers has seen a decline of 26.79%, reflecting broader challenges in the market. Currently, the stock is trading near its 52-week low of $13.74, which suggests a challenging environment for recovery.

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements.

The company’s recent collaboration with Novo Nordisk to provide FDA-approved GLP-1 medications highlights its commitment to expanding access to innovative health solutions. With more than 2 million subscribers, Hims & Hers is positioned as a leading platform in the consumer health market.

Hims & Hers Earnings & Analyst Outlook

Hims & Hers Health is slated to provide its next financial update on May 4, 2026 (estimated).

  • EPS Estimate: 2 cents (Down from 20 cents)
  • Revenue Estimate: $618.44 million (Up from $586.01 million)
  • Valuation: P/E of 39.9x (Indicates premium valuation)

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $31.69. Recent analyst moves include:

  • TD Cowen: Hold (Lowers Target to $23.00) (March 27)
  • Leerink Partners: Market Perform (Raises Target to $25.00) (March 16)
  • Barclays: Overweight (Raises Target to $29.00) (March 11)

Hims & Hers Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Hims & Hers Health, highlighting its strengths and weaknesses compared to the broader market:

  • Value: 3.72 — The stock is trading at a premium relative to peers.
  • Growth: 44.24 — Indicates moderate growth potential.
  • Momentum: 2.36 — Stock is underperforming the broader market.

The Verdict: Hims & Hers Health’s Benzinga Edge signal reveals a mixed profile with weak momentum and moderate growth potential, suggesting challenges ahead in a competitive market.

Hims & Hers Top ETF Exposure

  • SPDR Portfolio S&P 600 Small Cap ETF (NYSE:SPSM): 0.60% Weight
  • SPDR S&P 600 Small Cap Growth ETF (based on S&P SmallCap 600 G (ARCA: SLYG): 1.17% Weight
  • Vanguard S&P Small-Cap 600 Index Fund ETF (NYSE:VIOO): 0.64% Weight

Significance: Because HIMS carries meaningful weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

Hims & Hers Price Action

HIMS Stock Price Activity: Hims & Hers Health shares were down 2.10% at $19.90 during premarket trading on Tuesday, according to Benzinga Pro data.

Image via Shutterstock.